66th ASH Annual Meeting: 636. Myelodysplastic Syndromes: Basic and Translational: Poster I

Symposia: Myelodysplastic Syndromes: Basic and Translational Oral and Poster Abstracts
Poster

Research, Fundamental Science, MDS, Artificial intelligence (AI), Acquired Marrow Failure Syndromes, Acute Myeloid Malignancies, AML, Adult, Translational Research, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, CHIP, Elderly, Genetic Disorders, Genomics, Bioinformatics, Chronic Myeloid Malignancies, Hematopoiesis, CMML, Diseases, Treatment Considerations, Immunology, Non-Biological therapies, Computational biology, Myeloid Malignancies, Biological Processes, Technology and Procedures, Study Population, Multi-systemic interactions, Human, Pathogenesis, Measurable Residual Disease , Machine learning, Omics technologies

Halls G-H (San Diego Convention Center)

1809

A Study on the Effect of Luspatercept on Regulatory T Cells and Myeloid Derived Suppressor Cells in Low Risk Myelodysplastic Syndrome with Ring Sideroblasts

Stefania Leone^1,2^*, Francesco Grimaldi, MD³^*, Mara Memoli⁴^*, Flavia Carriero⁵^*, Giulia Scalia⁶^*, Annamaria Vincenzi⁷^*, Giuseppe Cerciello⁸^*, Fabrizio Pane⁹, Alessandra Picardi, MD¹⁰^*, Giuseppe Terrazzano⁵^*, Giuseppina Ruggiero¹¹^* and Valentina Rubino¹¹^*

¹University federico II of Naples, Naples, Italy
²AORN Cardarelli, Naples, Italy
³Department of Clinical Medicine and Surgery, Hematology Unit, University of Naples Federico II, Napoli, Italy
⁴Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Naples, Italy
⁵Department of Sciences, University of Basilicata, Potenza, Italy
⁶Centre for Advanced Biotechnology (CEINGE), Naples, Italy
⁷Aou-Federico II, Naples, Naples, ITA
⁸Hematology, "San Pio" Hospital of Benevento, Naples, ITA
⁹Division of Hematology and SCT Unit, Federico II University, Naples, Naples, Italy
¹⁰Stem Cell Transplant Program AORN Cardarelli, Naples and Biomedicine and Prevencion Department of Tor Vergata University, Rome, Naples / Rome, Italy
¹¹Department of Translational Medicine, University of Naples Federico II, Naples, Italy

1810

Clonal Dissection of MDS and Secondary AML Resolves Shared Splicing Neoantigens and Mechanistic Underpinnings of Hypomethylating Agent Therapeutic Response

Xuan Zhang, PhD¹^*, Guangyuan Li²^*, Anna Oliverio³^*, Jennifer VanOudenhove, PhD⁴, Amy E. DeZern, MD^5,6, Gabriel Ghiaur, MD, PhD⁷, Stephanie Halene, MD⁸, H. Leighton Grimes, PhD^9,10 and Nathan Salomonis, PhD¹¹^*

¹Division of Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
²Perlmutter Cancer Center, New York University, New York City, NY
³Division of Biomedical Informatics, Cincinnati Children's Hosptial, Cincinnati, OH
⁴Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁶The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
⁷Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, John's Hopkins Hospital, Baltimore, MD
⁸Yale Univ. School of Medicine, New Haven, CT
⁹Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
¹⁰Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH
¹¹Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH

1811

Elucidating the Interplay between ddx41 and cux1 mutations in Hematopoiesis in Danio Rerio

Valerie Awad, MS¹^* and Teresa V. Bowman, PhD²

¹Developmental and Molecular Biology, Albert Einstein College of Medicine, New York
²Department of Oncology, Department of Molecular and Developmental Biology, Albert Einstein College of Medicine, New York, NY

1812

Tet2 Loss in Hematopoietic Stem Cells Triggers Chromatin Reorganization through DNA Methylation Shifts

Rahul Roy, MSc¹^*, Manoj Pillai, MD¹ and Prajwal Boddu, MD²

¹Yale University, New Haven, CT
²Yale University, East Lyme, CT

1813

SF3B1 Mutations Lead to Changes in Fine-Scale Chromatin Organization through Impaired Transcription

Rahul Roy, MSc¹^*, Abhishek Gupta¹^*, Manoj Pillai, MD¹ and Prajwal Boddu, MD²

¹Yale University, New Haven, CT
²Yale University, East Lyme, CT

1814

Distinct Transcriptomic Cell States Differentiate Low-Risk MDS from Healthy Marrow

Pawan Bhat, BSc¹, Joseph C. Van Amburg, MS²^*, Thomas J. Gracie, MD³^*, Justin A Cartailler, BA⁴^*, Chad R Potts, BS⁴^*, Alexander G. Bick, MD, PhD⁵^*, Robert Welner, PhD⁶ and Brent Ferrell Jr., MD^4,7

¹School of Medicine, Program in Cancer Biology, Vanderbilt University, Nashville, TN
²School of Medicine, Human Genetics Program, Vanderbilt University, Nashville, TN
³Internal Medicine Residency, Vanderbilt University Medical Center, Nashville, TN
⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
⁵Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN
⁶Division of Hematology and Oncology, Department of Medicine, UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
⁷Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN

1815

MISTRG6kit^W41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model

Amro Baassiri, MD, PhD¹^*, Jamie Maziarz²^*, Holly Nicole Blackburn, MD³^*, Hannah Maul-Newby, PhD²^*, Jennifer VanOudenhove, PhD^1,4, Xuan Zhang, PhD⁵^*, Martin Matthews, MS¹^*, Sambuddha Paul, MS²^*, Wei Liu²^*, Esen Sefik, PhD⁶^*, Nathan Salomonis, PhD⁷^*, H. Leighton Grimes, PhD⁸, Richard Flavell, PhD, FRS³^* and Stephanie Halene, MD⁹

¹Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT
²yale university, new haven
³Yale University, New Haven, CT
⁴Yale Cancer Center, Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
⁵Division of Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
⁶Yale University School of Medicine, New Haven, CT
⁷Division of Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH
⁸Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH
⁹Yale Univ. School of Medicine, New Haven, CT

1816

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Jeremy Connors¹^*, Linda Zhang²^*, Hidetaka Uryu, MD, PhD³^*, Koji Sasaki, MD⁴, Jennifer Padilla²^*, Zongrui Li⁵^*, Ken Furudate, DMD, PhD⁴^*, Tomoyuki Tanaka¹^*, Courtney D. DiNardo, MD, MSc⁶, Nicholas J. Short, MD⁴, Naval Daver, MD⁷, Gautham Borthakur⁸^*, Farhad Ravandi, MBBS⁹, Tapan M. Kadia, MD⁴, Hagop M. Kantarjian, MD⁴, Elias Jabbour, MD¹⁰, Simona Colla, PhD¹¹, Branko Cuglievan, MD¹², Andrew Futreal, PhD¹³^*, Adam S. Sperling, MD, PhD¹⁴, Guillermo Garcia-Manero, MD⁴, Margaret Goodell, PhD¹⁵ and Koichi Takahashi, MD, PhD¹⁶

¹The University of Texas MD Anderson Cancer Center, Houston
²Baylor College of Medicine, Houston
³Leukemia, The UNIVERSITY of TEXAS, M.D. Anderson, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Leukemia, MD Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁷MD Anderson Cancer Center, Houston, TX
⁸The University of Texas MD Anderson Cancer Center, Houston, TX
⁹Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁰Department of Leukemia, University of Texas M.D. Anderson Cancer Ctr., Houston, TX
¹¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston
¹²Division of Pediatrics, MD Anderson Cancer Center, Houston, TX
¹³Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁴Dana-Farber Cancer Institute, Boston, MA
¹⁵Department of Molecular Cell Biology, Baylor College of Medicine, Houston, TX
¹⁶Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX

1817

High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine

Maha M Kamel, MBioChem, BScPharm^1,2^*, Nirmal Robinson, M.Pharm, PhD³^*, Monika Kutyna, PhD^4,5^*, Kelly Lim, MSc, BSc^1,2^*, Chloe Thompson-Peach, PhD^1,2^*, Steven W Lane, MBBS, PhD, FRCPA, FRACP⁶, David T Yeung, MBBS, PhD, BSc, FRACP, FRCPA⁵, Agnes S. M. Yong, MD, PhD^2,7, David M Ross, MD, PhD, FRACP, FRCPA^2,8^*, Devendra Hiwase, MD, MBBS, PhD, FRACP, FRCPA^5,9 and Daniel Thomas, MD, PhD, FRACP, FRCPA^5,8,10

¹Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
²South Australian Health and Medical Research Institute, Adelaide, Australia
³Centre for Cancer Biology, University of South Australia, Adelaide, Australia
⁴Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
⁵South Australian Health and Medical Research Institute, Adelaide, SA, Australia
⁶Cancer Program, QIMR Berghofer Medical Research Institute, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
⁷Haematology Department, Royal Perth Hospital, Perth, Australia
⁸Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia
⁹Department of Haematology, Central Adelaide Local Health Network, Adelaide, SA, Australia
¹⁰Central Adelaide Local Health Network, Adelaide, SA, Australia

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

636.P1.26 636. Myelodysplastic Syndromes: Basic and Translational: Poster I